China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®
Paris, France - August 8, 2017 - Sanofi announced today that it filed a patent infringement suit against Merck Sharp & Dohme Corp. ("Merck") on August 8, 2017 in the United States District Court for the District of New Jersey. In its suit Sanofi alleges infringement of two patents.
The suit was triggered by a notification received from Merck in late June, in which Merck stated that it had filed an NDA (505(b)(2) New Drug Application) with FDA for an insulin glargine vial drug product. Merck also stated that its NDA included a paragraph IV certification challenging all of the Sanofi patents then listed in the FDA Orange Book for Sanofi's Lantus® and Lantus® SoloStar® products.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Contacts:
| Media Relations Ashleigh Koss Tel: +1 (908) 981-8745 Mobile: +1 (908) 205-2572 [email protected] | Investor Relations George Grofik Tel. +33 (0) 1 53 77 45 45 [email protected] |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/77fe10b9-ef21-49d6-82d8-04a6516ee80a
